ArticlePituitary2025
Oral and gut microbiota after acromegaly treatment: prospective assessment and insights from machine learning.
Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acromegaly and colorectal cancer risk: emerging roles of the gut microbiota.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeThe human endocrine system and microbiota interact bidirectionally. Patients with acromegaly have distinct oral and gut microbiota profiles. The study aims to investigate the effects of acromegaly treatment on oral and fecal microbiota and evaluate their associations with insulin-like growth factor-1 (IGF-1) normalization. The predictive value of baseline microbiota-based machine learning algorithms regarding treatment outcomes is also analyzed.
methodsOral and fecal microbiota samples were prospectively collected from newly diagnosed acromegaly patients before and one year post-treatment. Following DNA isolation 16 S rRNA sequencing was performed, and bioinformatic analyses were conducted.
resultsA total of 19 patients were included (10 female(52.6%); mean age 48.8 ± 12.1 years). Seven patients achieved remission with surgery alone (Group 1), seven with combined surgical and medical treatment (Group 2), while five did not achieve remission (Group 3). Alpha and beta diversities were similar but microbial compositions differed significantly among the groups. In prospective analyses of Group 1 and combined Groups 1 and 2, microbiota profiles changed significantly. In Group 1, decrease in IGF-1 levels correlated positively with oral Succinivibrio. The developed classification model, using baseline microbiota profiles, accurately distinguished between the groups, and identified patients who achieved complete remission after surgery alone.
conclusionOral and fecal microbiota compositions in patients with acromegaly significantly change with treatment modalities and remission status with some taxa correlating with IGF-1 normalization. The findings provide preliminary evidence that microbiota may help predict treatment response. Further studies with larger patient populations are needed to validate the results.
Indexed as
Identifiers
41461980What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.